Literature DB >> 29092914

Influence of socioeconomic factors on pregnancy outcome in women with structural heart disease.

Iris M van Hagen1, Sara Baart1, Rebekah Fong Soe Khioe2, Karen Sliwa-Hahnle3, Nasser Taha4, Malgorzata Lelonek5, Luigi Tavazzi6, Aldo Pietro Maggioni7, Mark R Johnson8, Nikolaos Maniadakis9,10, Richard Fordham2, Roger Hall11, Jolien W Roos-Hesselink1,12.   

Abstract

OBJECTIVE: Cardiac disease is the leading cause of indirect maternal mortality. The aim of this study was to analyse to what extent socioeconomic factors influence the outcome of pregnancy in women with heart disease.
METHODS: The Registry of Pregnancy and Cardiac disease is a global prospective registry. For this analysis, countries that enrolled ≥10 patients were included. A combined cardiac endpoint included maternal cardiac death, arrhythmia requiring treatment, heart failure, thromboembolic event, aortic dissection, endocarditis, acute coronary syndrome, hospitalisation for cardiac reason or intervention. Associations between patient characteristics, country characteristics (income inequality expressed as Gini coefficient, health expenditure, schooling, gross domestic product, birth rate and hospital beds) and cardiac endpoints were checked in a three-level model (patient-centre-country).
RESULTS: A total of 30 countries enrolled 2924 patients from 89 centres. At least one endpoint occurred in 645 women (22.1%). Maternal age, New York Heart Association classification and modified WHO risk classification were associated with the combined endpoint and explained 37% of variance in outcome. Gini coefficient and country-specific birth rate explained an additional 4%. There were large differences between the individual countries, but the need for multilevel modelling to account for these differences disappeared after adjustment for patient characteristics, Gini and country-specific birth rate.
CONCLUSION: While there are definite interregional differences in pregnancy outcome in women with cardiac disease, these differences seem to be mainly driven by individual patient characteristics. Adjustment for country characteristics refined the results to a limited extent, but maternal condition seems to be the main determinant of outcome. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  congenital heart disease; global health; heart failure; pregnancy; valvular heart disease

Mesh:

Year:  2017        PMID: 29092914     DOI: 10.1136/heartjnl-2017-311910

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  4 in total

1.  Caring for Pregnant Women with Rheumatic Heart Disease: A Qualitative Study of Health Service Provider Perspectives.

Authors:  Geraldine Vaughan; Angela Dawson; Michael Peek; Jonathan Carapetis; Vicki Wade; Elizabeth Sullivan
Journal:  Glob Heart       Date:  2021-12-22

2.  Neonatal Risk in Children of Women With Congenital Heart Disease: A Cohort Study With Focus on Socioeconomic Status.

Authors:  Stine Kloster; Janne S Tolstrup; Morten Smærup Olsen; Søren Paaske Johnsen; Lars Søndergaard; Dorte Guldbrand Nielsen; Annette Kjær Ersbøll
Journal:  J Am Heart Assoc       Date:  2019-10-28       Impact factor: 5.501

3.  High Burden of Cardiac Disease in Pregnancy at a National Referral Hospital in Western Kenya.

Authors:  Rebecca Lumsden; Felix Barasa; Lawrence P Park; Christian B Ochieng; Joy M Alera; Heather C Millar; Gerald S Bloomfield; Astrid Christoffersen-Deb
Journal:  Glob Heart       Date:  2020-02-07

4.  Predictors of maternal and neonatal complications in women with severe valvular heart disease during pregnancy in Tunisia: a retrospective cohort study.

Authors:  Rania Hammami; Mohamed Ali Ibn Hadj; Yosra Mejdoub; Amine Bahloul; Selma Charfeddine; Leila Abid; Samir Kammoun; Abdallah Dammak; Kais Chaabene
Journal:  BMC Pregnancy Childbirth       Date:  2021-12-08       Impact factor: 3.007

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.